Skip to main content
Screenshot of alnylam.com

Live website intelligence

alnylam.com

Alnylam® Pharmaceuticals

Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company

Last refresh

Updated 16d ago

Analyst read

Professional

5/100 trustHealth & FitnessStale snapshot

Detected stack

Unknown

Quick read

How to read alnylam.com quickly

alnylam.com looks like health & fitness. Traffic estimates are limited, so use the trust and structure modules first. Current AI trust scoring is 5/100.

What to do next

  • The stack appears to include Unknown.
  • Open the Traffic tab if you need audience scale and geography before outreach.
  • Open the Business tab if trust, monetization, or positioning is your first decision filter.

Provider Completeness

39/56 fields populated (70%)

11 providers

Providers with missing fields

publisher: 3/5files: 2/3traffic: 0/10radar: 0/4
View field-level status

visual: 4/4

All expected fields present

meta: 3/3

All expected fields present

seo: 5/5

All expected fields present

dns: 4/4

All expected fields present

ads: 5/5

All expected fields present

publisher: 3/5

Missing: directCount, resellerCount

files: 2/3

Missing: robotsSitemapUrls

traffic: 0/10

Missing: monthlyVisits, globalRank, countryRank, bounceRate, avgVisitDuration, pagesPerVisit, topCountry, topRegions, topKeywords, trafficSources

whois: 6/6

All expected fields present

radar: 0/4

Missing: globalRank, rankBucket, categories, sourceTimestamp

ai: 7/7

All expected fields present

Why this module matters

Business signals help answer “is this a real opportunity?”

Use the business tab to understand trust, monetization, audience fit, and brand posture before you spend time on outreach, partnerships, or competitive teardown work.

  • Trust score and sentiment are your first risk screen.
  • Business summary and audience notes speed up qualification.
  • Ads and monetization patterns reveal how the site captures value.

Business Intelligence

Business Profile

Alnylam Pharmaceuticals is a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics to silence disease-causing genes and treat genetic and other diseases.

Business ModelB2B2C Pharmaceutical/Biotech
Target AudiencePatients with genetic and rare diseases, healthcare professionals, medical researchers, investors, and healthcare systems

Classification

CategoryHealth & Fitness
Sub-CategoryPharmaceuticals
RNAi therapeuticsbiotechnologygenetic medicinepharmaceuticalsdrug developmentrare diseasesgene silencing

Trust & Risk

Trust Assessment

Trust Score5/100
SentimentProfessional
Spam DetectionClean

Google Ads Transparency

Is AdvertiserActive Advertiser
Advertiser Names
Greater Than One, Inc.
Advertiser IDs
AR06968348455076888577
Ad Count1
has_advertiser_idhas_creative_results

Publisher Monetization

ads.txtMissing

Monetization Signals

missing_ads_txt

AI Visual Analysis

Design StyleCorporate Healthcare
VibeTrustworthy, Innovative, Hopeful
UI Score8/100
Detected Logo TextAlnylam

IAB Taxonomy

IAB CategoryHealth & Fitness
IAB Sub-CategoryPharmaceuticals
Confidence98%
RNAi therapeuticsbiotechnologygenetic medicinepharmaceuticalsdrug developmentrare diseasesgene silencing

Business Insights

Business Model

B2B2C Pharmaceutical/Biotech model detected

Trust Level

Low trust with 5/100 score

Audience

Patients with genetic and rare diseases, healthcare professionals, medical researchers, investors, and healthcare systems

Keep exploring

Keep exploring from this report

Good pSEO pages should not strand the visitor. These links keep the journey moving through adjacent directories and comparable live reports.

Need fresh data for another site? Trigger a fresh analysis or open the directory to continue browsing.